CRL-8027 OKT 11雜交瘤細胞抗CD2，ATCC 細胞|細胞系|細胞株|腫瘤細胞|細胞|貼壁細胞|懸浮細胞|,細胞庫管理規范,提供的細胞株背景清楚,提供參考文獻和*培養條件
CRL-8027 OKT 11雜交瘤細胞抗CD2，ATCC 細胞|細胞系|細胞株|腫瘤細胞|細胞|貼壁細胞|懸浮細胞|,細胞庫管理規范,提供的細胞株背景清楚,提供參考文獻和*培養條件
8027 OKT 11雜交瘤細胞抗CD2 的詳細介紹
CRL-8027 OKT 11雜交瘤細胞抗CD2
| ATCC? Number: | CRL-8027? | Price: | $399.00 |
| Designations: | OKT 11 | | Depositors: | Ortho Pharmaceutical Corporation | | Isotype: | IgG1 | | Biosafety Level: | 1 | | Shipped: | frozen | | Medium & Serum: | See Propagation | | Growth Properties: | suspension | | Organism: | Mus musculus （B cell）; Mus musculus （myeloma） （mouse （B cell）; mouse （myeloma）） | | Morphology: | lymphoblast
| | Source: | Cell Type: hybridoma: B lymphocyte; | | Cellular Products: | immunoglobulin; monoclonal antibody; against human T cell （human T lymphocyte） and human E rosette positive thymocytes （human thymic lymphocyte）; against CD2 | | Permits/Forms: | In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimay responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location. |
| | Comments: | Mice were immunized with human T cell leukemia cells （acute lymphoblastic leukemia）.
Spleen cells were fused with P3X63Ag8.U1 myeloma cells. | | Propagation: | ATCC complete growth medium: Iscove's modified Dulbecco's medium, 80%; fetal bovine serum, 20% | | Subculturing: | Medium Renewal: Every 2 to 3 days
Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml. | | References: | 3507: Kung PC, Goldstein G. Monoclonal antibody to a human T cell antigen and methods of preparing same. US Patent 4,364,937 dated Dec 27 1982 |
|
15
